The FDA granted accelerated approval to selinexor (Xpovio, Karyopharm) in combination with dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is resistant to several other treatments, including at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
“While there is no cure for multiple myeloma, there are FDA-approved